Xigris Serious Bleeds Can Be Minimized If Invasive Procedures Avoided - Lilly
Executive Summary
Serious bleeding events as a result of Xigris administration can be reduced by avoiding invasive procedures during the drug infusion period, Lilly indicates in advisory committee briefing documents for the sepsis agent.
You may also be interested in...
Xigris meeting rescheduled
FDA's Anti-Infective Drugs Advisory Committee will consider Lilly's Xigris (drotrecogin alfa) BLA on Oct. 16 at the Hilton in Gaithersburg, Md. starting at 8:30 a.m. The original Sept. 12 meeting was rescheduled following the terrorist attacks on Washington, D.C. and New York City (1"The Pink Sheet" Sept. 17, pp. 10 & 212)
Xigris meeting rescheduled
FDA's Anti-Infective Drugs Advisory Committee will consider Lilly's Xigris (drotrecogin alfa) BLA on Oct. 16 at the Hilton in Gaithersburg, Md. starting at 8:30 a.m. The original Sept. 12 meeting was rescheduled following the terrorist attacks on Washington, D.C. and New York City (1"The Pink Sheet" Sept. 17, pp. 10 & 212)
FDA Xigris Efficacy Analysis Suggests APACHE II Test Can Guide Therapy
An FDA analysis of Lilly's Xigris Phase III efficacy data suggests that the APACHE II sepsis scale may be a useful guide for identifying candidates for therapy.